• 1

    Cortese VS, Grooms DL, Ellis JA, et al. Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of modified-live virus vaccine. Am J Vet Res 1998;59:14091413.

    • Search Google Scholar
    • Export Citation
  • 2

    McClurkin AW, Littledike ET, Cutlip RC. Production of cattle immunotolerant to bovine viral diarrhea virus (BVDV). Can J Comp Med 1984;48:156161.

    • Search Google Scholar
    • Export Citation
  • 3

    Ficken M, Jeevaerathnam S, Wen Welch SK, et al. BVDV fetal infection with selected isolates. In: International symposium: bovine viral diarrhea virus: a 50 year review. Ithaca, NY: Cornell University Press, 1996;110112.

    • Search Google Scholar
    • Export Citation
  • 4

    Kaeberle ML, Maxwell D, Johnson E. Efficacy of inactivated bovine viral diarrhea virus vaccines in a cow herd. In: Animal science leaflet R 701. Ames, Iowa: Iowa State University Press, 1990;4243.

    • Search Google Scholar
    • Export Citation
  • 5

    Meyling A, Rensholt L, Dalsgaard K, et al. Experimental exposure of vaccinated and non-vaccinated pregnant cattle to isolates of bovine viral diarrhea virus (BVDV), in Proceedings. Commission Eur Communities Semin Res Anim Husbandry 1987;225231.

    • Search Google Scholar
    • Export Citation
  • 6

    Harkness JW, Roeder PL, Drew T, et al. The efficacy of an experimental inactivated BVD-MD vaccine, in Proceedings. Commission Eur Communities Semin Res Anim Husbandry 1987;233250.

    • Search Google Scholar
    • Export Citation
  • 7

    Brownlie J, Clarke MC, Hooper LB, et al. Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Vet Rec 1995;137:5862.

    • Search Google Scholar
    • Export Citation
  • 8

    Frey HR, Eicken K. Untersuchungen uber die Wirksamkeit einer inaktivierten BVD-Vakzine zur Erhohung der Sicherheit einer BVD-Lebendvakzine. Tierarztl Umsch 1995;50:8693.

    • Search Google Scholar
    • Export Citation
  • 9

    Cortese VS, West KH, Hassard LE, et al. Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type-II isolate of bovine viral diarrhea virus. J Am Vet Med Assoc 1998;213:13121319.

    • Search Google Scholar
    • Export Citation
  • 10

    Dean HJ, Leyh RL. Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine 1999;17:11171124.

    • Search Google Scholar
    • Export Citation
  • 11

    Makoschey B, Janssen MG, Vrijenhoek MP, et al. An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2. Vaccine 2001;19:32613268.

    • Search Google Scholar
    • Export Citation
  • 12

    Shimazaki T, Nakamura S, Taguchi K, et al. Efficacy of bovine viral diarrhea vaccine used in Japan against bovine viral diarrhea virus type 2 strain 890. J Vet Med Sci 2003;65:263266.

    • Search Google Scholar
    • Export Citation
  • 13

    Fairbanks K, Schnackel J, Chase CC. Evaluation of a modified live virus type-1a bovine viral diarrhea virus vaccine (Singer strain) against a type-2 (strain 890) challenge. Vet Ther 2003;4:2434.

    • Search Google Scholar
    • Export Citation
  • 14

    Brock KV, Cortese VS. Experimental fetal challenge using type II bovine viral diarrhea virus in cattle vaccinated with modified-live virus vaccine. Vet Ther 2001;2:354360.

    • Search Google Scholar
    • Export Citation
  • 15

    Fairbanks KK, Rinehart CL, Ohnesorge WC, et al. Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc 2004;225:18981903.

    • Search Google Scholar
    • Export Citation
  • 16

    Kovacs F, Magyar T, Rinehart C, et al. The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection. Vet Microbiol 2003;96:117131.

    • Search Google Scholar
    • Export Citation
  • 17

    SAS/STAT procedures guide. Cary, NC: SAS Institute Inc.

Advertisement

Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation

View More View Less
  • 1 Pfizer Animal Health, 601 W Cornhusker Hwy, Lincoln, NE 68521
  • | 2 Pfizer Animal Health, 601 W Cornhusker Hwy, Lincoln, NE 68521
  • | 3 Pfizer Animal Health, 601 W Cornhusker Hwy, Lincoln, NE 68521
  • | 4 Pfizer Animal Health, 150 E 42nd St, New York, NY 10017

Abstract

Objective—To compare the efficacy of modified-live virus (MLV) vaccines containing either type 1 bovine viral diarrhea virus (BVDV) or types 1 and 2 BVDV in protecting heifers and their offspring against infection associated with heterologous noncytopathic type 2 BVDV challenge during gestation.

Design—Randomized controlled study.

Animals—160 heifers and their offspring.

Procedures—After inoculation with a placebo vaccine, 1 or 2 doses of an MLV vaccine containing type 1 BVDV, or 1 dose of an MLV vaccine containing both types 1 and 2 BVDV, heifers were bred naturally and challenge exposed with a type 2 BVDV field isolate between 62 and 104 days of gestation. Pregnancies were monitored; after parturition, virus isolation and immunohistochemical analyses of ear-notch specimens were used to determine whether calves were persistently infected. Blood samples were collected at intervals from heifers for serologic evaluation and virus isolation.

Results—Persistent infection was detected in 18 of 19 calves from heifers in the control group and in 6 of 18 calves and 7 of 19 calves from heifers that received 1 or 2 doses of the type 1 BVDV vaccine, respectively. None of the 18 calves from heifers that received the type 1–type 2 BVDV vaccine were persistently infected.

Conclusions and Clinical Relevance—Results suggest that the incidence of persistent BVDV infection among offspring from dams inoculated with 1 dose of the MLV vaccine containing types 1 and 2 BVDV was decreased, compared with 1 or 2 doses of the MLV vaccine containing only type 1 BVDV.

Contributor Notes

Dr. Ficken's present address is Benchmark BioLabs Inc, 521 W Industrial Lake Dr, Lincoln, NE 68528. Dr. Tucker's present address is Pfizer Animal Health, 7000 Portage Rd, Kalamazoo, MI 49001.

Supported by Pfizer Animal Health.

Address correspondence to Dr. Cortese